At final analysis of the core study ( data cutoff , October , 2012 ) , 2-year progression-free survival was higher in the imatinib group ( 592 % [ 95 % CI 509-665 ] ) than in the nilotinib group ( 516 % [ 430-595 ] ; hazard ratio 147 [ 95 % CI 110-195 ] ) .